Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer
Jaime Ceballos-Viro (1), José M López-Picazo (1), José L Pérez-Gracia (1), Jesús J Sola (2), Gregorio Aisa (2), Ignacio Gil-Bazo (1)
Fibrosing cholestatic hepatitis (FCH) is a variant of viral hepatitis reported in hepatitis B virus or hepatitis C virus infected liver, renal or bone transplantation recipients and in leukemia and lymphoma patients after conventional cytotoxic chemotherapy.
FCH constitutes a well-described form of fulminant hepatitis having extensive fibrosis and severe cholestasis as its most characteristic pathological findings. Here, we report a case of a 49-year-old patient diagnosed with small-cell lung cancer who developed this condition following conventional chemotherapy-induced immunosuppression.
This is the first reported case in the literature of FCH after conventional chemotherapy for a solid tumor. In addition to a detailed report of the case, a physiopathological examination of this potentially life-threatening condition and its treatment options are discussed.
CITATION World J Gastroenterol. 2009 May 14;15(18):2290-2.